Historically considered "heresy," re-biopsy in pancreatic cancer is now an everyday practice. Initial samples often yield insufficient tissue for comprehensive genomic analysis, making subsequent biopsies of metastatic sites necessary to guide precision treatment.

With only one-third of pancreatic cancer patients advancing to second-line treatment, oncologists must carefully select first-line therapies. This may involve choosing less toxic combinations to preserve patient fitness for subsequent treatments, like emerging KRAS inhibitors, rather than using the most aggressive option upfront.

The sharp rise in cancers like colorectal cancer among adults under 50 necessitates a shift in frontline diagnostics. Symptoms such as abdominal pain in a younger person, historically not a top cancer concern, must now prompt more serious consideration. Educating primary care and ER doctors to lower their diagnostic threshold for malignancy is critical.

Previously called "maturity onset diabetes" because it exclusively affected older adults, the name was officially changed to "Type 2 diabetes" as it became alarmingly common in children and young people, signifying a major public health shift.

Oncologists co-order tissue and liquid biopsies for new pancreatic cancer patients. This is crucial because tissue samples are insufficient for genomic testing in roughly 20% of cases, making the liquid biopsy an essential backup for treatment planning.

The standard of care for pancreatic cancer includes ordering both germline (inherited) and somatic (tumor-specific) genetic tests at the initial patient visit. This "point-of-care" approach is crucial for identifying targetable mutations early on.

Oncologists observe that newly diagnosed pancreatic cancer patients now frequently ask about clinical trials. This indicates a significant shift in patient education and empowerment, with individuals actively seeking the most novel treatments available from day one.

A key future goal in GI oncology is for systemic drugs to become so effective in early disease stages that they diminish or eliminate the need for surgery and radiation. This would spare patients from life-changing procedures like organ removal for gastric, rectal, and pancreatic cancers.

Unlike breast or lung cancer where a biomarker's effectiveness persists across treatment stages, biomarkers in upper GI cancers often fail to show similar efficacy when moved from one line of therapy to another. This suggests a more variable and rapidly changing tumor biology.